# US 2024/0197727 A1 · Solid dispersions comprising amorphous pimobendan and one or more stabilizing polymers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197727 A1
- Document ID: US20240197727A1
- Status: Published application
- Kind: A1
- Application number: 18/537,432
- Filed: 2023-12-12
- Published: 2024-06-20
- Earliest claimed: 2022-12-15
- Assignees: Boehringer Ingelheim Vetmedica GmbH
- Applicants: Boehringer Ingelheim Vetmedica GmbH
- Inventors: Péter LACZAY; Péter Lajos Sóti
- Web page: https://patentgrep.com/patent/US20240197727A1

## CPC

- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1694: {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/2068: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/2013)}
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/585: containing lactone rings, e.g. oxandrolone, bufalin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/146: {with organic macromolecular compounds}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to novel solid dispersions comprising amorphous pimobendan and one or more stabilizing polymers as well as processes of manufacturing thereof and corresponding pharmaceutical compositions.

## Claims

### Claim 1

A solid dispersion comprising, preferably consisting of, amorphous pimobendan, preferably substantially amorphous pimobendan, and one or more stabilizing polymers.

### Claim 2 (depends on 1)

The solid dispersion according to claim 1, wherein the one or more stabilizing polymers is selected from the group consisting of: polymerization products of N-vinylpyrrolidone, vinyl acetate and vinylpyrrolidone mixed with vinyl acetate; as well as polymeric methacrylates.

### Claim 3 (depends on 2)

The solid dispersion according to claim 2, wherein the polymerization products of N-vinylpyrrolidone, vinyl acetate and vinylpyrrolidone mixed with vinyl acetate; as well as polymeric methacrylates are selected from the group consisting of: povidone (polyvinylpyrrolidone), polyvinyl alcohol and copovidone [poly-(1-vinylpyrrolidone-co-vinylacetate)]; and the polymeric methacrylates are selected from the group consisting of: polymeric butyl 2-methylprop-2-enoate; polymeric 2-(dimethylamino)ethyl 2-methylprop-2-enoate; and polymeric methyl 2-methylprop-2-enoate.

### Claim 4 (depends on 1, 2, 3)

The solid dispersion according to any one of claims 1 to 3, wherein the solid dispersion; and/or the one or more stabilizing polymers; and/or the polymerization products of N-vinylpyrrolidone, vinyl acetate and vinylpyrrolidone mixed with vinyl acetate; and/or polymeric methacrylates independently from each other do not comprise crospovidone (cross-linked polyvinylpyrrolidone, polyvinylpolypyrrolidone, PVPP).

### Claim 5 (depends on 1, 2, 3, 4)

The solid dispersion according to any one of claims 1 to 4, wherein the solid dispersion; and/or the one or more stabilizing polymers; and/or the polymerization products of N-vinylpyrrolidone, vinyl acetate and vinylpyrrolidone mixed with vinyl acetate; and/or polymeric methacrylates independently from each other do not comprise one or more hyperbranched polymers, optionally being selected from the group consisting of: dendritic polymers, dendrimers, arborol, cascade, cauliflower or star polymers, polydisperse hyperbranched polymers, dendrigraft polymers, or other high molecular weight polymers, which all have specific branched structure containing a center atom or a molecule, which can be monomeric or polymeric, from where three or more chains emanate; hyperbranched polyimines, hyperbranched polyurethanes, hyperbranched polyamides, hyperbranched polyesteramines, hyperbranched polyesteramides, hyperbranched polymers comprising hydroxyl groups, ester groups, amido groups and/or carboxyl groups, and polyesteramide hyperbranched polymers, such as one or more hyperbranched polyesteramide having tertiary amine end groups and/or having hydroxyl end groups.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The solid dispersion according to any one of claims 1 to 5, wherein the one or more stabilizing polymers is copovidone [poly-(1-vinylpyrrolidone-co-vinylacetate)], which is preferably the only stabilizing polymer in the solid dispersion.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The solid dispersion according to any one of claims 1 to 6, wherein pimobendan is present in an amount of 1% to 80% by weight relative to the weight of the solid dispersion, preferably in an amount of 5% to 40% by weight relative to the weight of the solid dispersion and more preferably in an amount of 10% to 20% by weight relative to the weight of the solid dispersion.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The solid dispersion according to any one of claims 1 to 7, wherein at least 70% of the pimobendan is present in amorphous form.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A process of preparing the solid dispersion according to any one of claims 1 to 8, wherein the solid dispersion is prepared by a melting-based process, preferably by hot melt extrusion, or a solvent evaporation-based process, preferably by spray drying.

### Claim 10 (depends on 9)

The process according to claim 9 being a hot melt extrusion process comprising the steps of:
(a) processing pimobendan and the one or more stabilizing polymers by means of a pharmaceutical extruder, preferably a screw extruder, more preferably a twin-screw extruder, preferably at a barrel temperature of 120-200° C., more preferably at a barrel temperature of 150-180° C., to obtain an extrudate,
(b) comminuting the extrudate obtained in step (a) by using a granulator or pelletizer to obtain a granulate, and
(c) milling the granulate obtained in step (b) to obtain a solid dispersion, the solid dispersion preferably comprising particles with an average diameter of less than 500 μm.

### Claim 11 (depends on 9)

The process according to claim 9 being a spray drying process comprising the steps of:
(a) dispersing or dissolving pimobendan and the one or more stabilizing polymers in one or more solvents, preferably selected from the group consisting of: dichloromethane, chloroform, ethanol, methanol, 2-propanol, ethyl acetate, acetone, water and mixtures thereof, to obtain a feed solution,
(b) pumping the feed solution obtained in step (a) through an atomizer into a drying chamber, and
(c) removing the one or more solvents in the drying chamber to obtain a solid dispersion, the solid dispersion preferably comprising particles with an average diameter of less than 500 μm.

### Claim 12 (depends on 9, 10, 11)

A solid dispersion comprising, preferably consisting of, amorphous pimobendan, preferably substantially amorphous pimobendan, and one or more stabilizing polymers obtainable by the process according to any one of claims 9 to 11.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 12)

A pharmaceutical composition comprising the solid dispersion according to any one of claims 1 to 8 and 12 and one or more pharmaceutically acceptable excipients, optionally additionally comprising crystalline form(s) of pimobendan (preferably according to FIG. 1), wherein preferably the pharmaceutical composition is a tablet, more preferably a chewable tablet.

### Claim 14 (depends on 13)

The pharmaceutical composition according to claim 13, wherein the pharmaceutically acceptable excipients comprise at least one filler, at least one disintegrant, at least one lubricant and at least one flavor.

### Claim 15 (depends on 13, 14)

The pharmaceutical composition according to any one of claims 13 to 14, further comprising pharmaceutically effective amounts of one or more further active ingredients selected from the groups of angiotensin converting enzyme (ACE) inhibitors, aldosterone antagonists and/or loop diuretics.

### Claim 16 (depends on 15)

The pharmaceutical composition according to claim 15, wherein the optional one or more further active ingredients selected from the groups of angiotensin converting enzyme (ACE) inhibitors, aldosterone antagonists and/or loop diuretics are independently from each other benazepril, spirolactone, furosemide aid/or derivatives thereof, in free form or in the form of a physiologically acceptable salt.

### Claim 17 (depends on 11, 12, 13, 14)

The pharmaceutical composition according to anyone of claims 11 to 14 selected from the group consisting of: A, B, C, D and E (the crystalline pimobendan depicted in the tables below preferably refers to the crystalline pimobendan according to FIG. 1):
Components
Amounts (% w/w)
Solid dispersion of substantially amorphous
6.3
pimobendan and one or more stabilizing polymers
Lactose monohydrate
26.1
Microcrystalline cellulose
20.6
Pork liver powder
20.0
Dried yeast
10.0
Starch, pregelatinized
8.0
Sodium starch glycolate
6.0
Talc
2.0
Magnesium stearate
1.0
Components
Amounts (% w/w)
Solid dispersion of substantially amorphous
5.0
pimobendan and one or more stabilizing polymers
Lactose monohydrate
27.4
Microcrystalline cellulose
20.6
Pork liver powder
20.0
Dried yeast
10.0
Starch, pregelatinized
8.0
Sodium starch glycolate
6.0
Talc
2.0
Magnesium stearate
1.0
Components
Amounts (% w/w)
Solid dispersion of substantially amorphous
3.1
pimobendan and one or more stabilizing polymers
Pimobendan crystalline
0.3
Lactose monohydrate
29.0
Microcrystalline cellulose
20.6
Pork liver powder
20.0
Dried yeast
10.0
Starch, pregelatinized
8.0
Sodium starch glycolate
6.0
Talc
2.0
Magnesium stearate
1.0
Components
Amounts (% w/w)
Solid dispersion of substantially amorphous
3.1
pimobendan and one or more stabilizing polymers
Pimobendan crystalline
0.3
Lactose monohydrate
30.0
Microcrystalline cellulose
29.6
Pork liver powder
20.0
Starch, pregelatinized
8.0
Sodium starch glycolate
6.0
Talc
2.0
Magnesium stearate
1.0
Components
Amounts (% w/w)
Solid dispersion of substantially amorphous
6.3
pimobendan and one or more stabilizing polymers
Lactose monohydrate
27.0
Microcrystalline cellulose
29.7
Pork liver powder
20.0
Starch, pregelatinized
8.0
Sodium starch glycolate
6.0
Talc
2.0
Magnesium stearate
1.0
